NASDAQ: AURAAura Biosciences Inc Stock
$7.01-0.04 (-0.57%)
Updated May 1, 2026
AURA Price
$7.01
Fair Value Price
$0.70
Market Cap
$449.69M
52 Week Low
$4.35
52 Week High
$7.68
P/E
-3.98x
P/B
3.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$106.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$85M
Beta
1.12
Next Earnings
May 7, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AURA Overview
Aura Biosciences, Inc. is a biotechnology company that develops ocular and urologic cancer treatments. The company is developing a virus-like drug conjugate pipeline to treat high unmet need cancers that either have no approved drugs available or are poorly managed with currently available treatments. The company was incorporated in 2009 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AURA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important AURA news, forecast changes, insider trades & much more!
AURA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AURA ($7.01) is overvalued by 903.77% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AURA ($7.01) is not significantly undervalued (903.77%) relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AURA due diligence checks available for Premium users.
Valuation
AURA fair value
Fair Value of AURA stock based on Discounted Cash Flow (DCF)
Price
$7.01
Fair Value
$0.70
Overvalued by
903.77%
AURA ($7.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AURA ($7.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.98x
Industry
29.05x
Market
18.83x
AURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.28x
Industry
4.9x
AURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.6M
Profit Margin
0%
AURA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$169.4M
Liabilities
$32.5M
Debt to equity
0.24
AURA's short-term assets ($149.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AURA's short-term assets ($149.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AURA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.5M
Investing
$29.8M
Financing
$2.8M
AURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AURA vs Biotech Stocks
Aura Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.